First Time Loading...

Novo Nordisk A/S

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
Price: 159.81 USD -1.94% Market Closed
Updated: May 31, 2023

DCF Value

This DCF valuation model was created by Alpha Spread and was last updated on May 31, 2023.

Estimated DCF Value of one NVO stock is 97.52 USD. Compared to the current market price of 159.81 USD, the stock is Overvalued by 39%.

Base Case
97.52 USD
Overvaluation 39%
DCF Value
Worst Case
Base Case
Best Case
DCF Value
Worst Case
Base Case
Best Case
DCF Value: 97.52 USD
Novo Nordisk A/S Competitors:
DCF Valuation
Jilin Jian Yisheng Pharmaceutical Co Ltd
Supernus Pharmaceuticals Inc
Seelos Therapeutics Inc
PKU HealthCare Corp Ltd
Zhejiang Nhu Co Ltd
Shanghai Fosun Pharmaceutical Group Co Ltd
Lyra Therapeutics Inc
Shanghai Kai Kai Industry Co Ltd

Present Value Calculation

The first step in the DCF calculation process is to estimate the company's future free cash flow. Once free cash flow is forecasted, it is discounted at a risk-appropriate discount rate. The resulting value is the present value of the company's free cash flow. You can change any model inputs below.

Available Valuation Models
1 valuation model available
Alpha Spread
Updated on May 31, 2023
Default Valuation
Create My Valuation Model
Other investors haven't shared any valuation models for Novo Nordisk A/S.
Model Settings
Discount Rate
Forecast Period
5 Years
Terminal Growth
Discount Rate
Terminal Growth
Growth Period
5 Years
Copy as My Model

DCF Model
Base Case Scenario

Rotate your device to view
DCF Model

To view the process of deriving the DCF Value of one share from the estimated Present Value, see the DCF Value Calculation block.

DCF Value Calculation

Depending on which type of operating model is chosen (equity or whole firm valuation model), the resulting value is either the value of equity or the value of the entire firm. In the case of the latter, to move from the value of the firm to the value of equity, liabilities are subtracted and assets are added.

Capital Structure
From Present Value to DCF Value

Present Value 1.5T DKK
+ Cash & Equivalents 12.2B DKK
+ Investments 11.8B DKK
Firm Value 1.6T DKK
- Debt 24.8B DKK
Equity Value 1.5T DKK
/ Shares Outstanding 2.3B
Value per Share 678.48 DKK
DKK / USD Exchange Rate 0.1437
NVO DCF Value 97.52 USD
Overvalued by 39%

To view the process of calculating the Present Value of Novo Nordisk A/S' future free cash flow, see the Present Value Calculation block.

Valuation Analysis

After the valuation process, in order to gain a deeper understanding of the relationship between risk and opportunity, it is useful to study the dynamic of company's valuation under various inputs to the DCF model in use.

DCF Financials
Financials used in DCF Calculation

219B 363B
Operating Income
93.5B 151B
84.3B 124B

Sensitivity Analysis
DCF Value Sensitivity Analysis

See Also

Similar Stocks
What is the DCF value of one NVO stock?

Estimated DCF Value of one NVO stock is 97.52 USD. Compared to the current market price of 159.81 USD, the stock is Overvalued by 39%.

The true DCF Value lies somewhere between the worst-case and best-case scenario values. This is because the future is not predetermined, and the stock's DCF Value is based almost entirely on the future of the company. Knowing the full range of possible stock DCF values gives a complete picture of the investment risks and opportunities.

How was the DCF Value calculated?

1. Present Value Calculation. Using the DCF Operating Model we project Novo Nordisk A/S's future free cash flow and discount it at a selected discount rate to calculate its Present Value (1.5T DKK).

2. DCF Value Calculation. We use the company's capital structure to calculate the total Equity Value based on the previously computed Present Value of the free cash flow. Dividing the Equity Value by the number of shares outstanding gives us the DCF Value of 97.52 USD per one NVO share.